Full Text Journal Articles by
Author Roscoe F Morton

Advertisement

Find full text journal articles






A Pathway Through the Bundle Jungle.

Blase Polite, Jeffery C Ward, John V Cox, Roscoe F Morton, John Hennessy, Ray Page, Rena M Conti,

J Oncol Pract (Journal of oncology practice)
[2016, 12(6):504-509]

Cited: 10 times

View full text PDF listing >>



Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]).

Terence T Sio, Pamela J Atherton, Brandon J Birckhead, David J Schwartz, Jeff A Sloan, Drew K Seisler, James A Martenson, Charles L Loprinzi, Patricia C Griffin, Roscoe F Morton, Jon C Anders, Thomas J Stoffel, Robert E Haselow, Rex B Mowat, Michelle A Neben Wittich, James D Bearden, Robert C Miller,

Radiotherapy-related dermatological toxicities over time have not been well quantified. We examined during and immediately following radiation therapy skin toxicities over time in a randomized study of mometasone furoate vs placebo during breast radiotherapy.Patients with breast cancer undergoing radiotherapy to the breast or chest wall were randomized. Symptoms related to ... Read more >>

Support Care Cancer (Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer)
[2016, 24(9):3847-3855]

Cited: 0 times

View full text PDF listing >>



Advertisement

Reply to M. Thompson et Al.

Blase Polite, Jeffery C Ward, John V Cox, Roscoe F Morton, John Hennessy, Ray Page, Rena M Conti,

J Oncol Pract (Journal of oncology practice)
[2015, 11(3):263-264]

Cited: 0 times

View full text PDF listing >>



Payment for oncolytics in the United States: a history of buy and bill and proposals for reform.

Blase N Polite, Jeffery C Ward, John V Cox, Roscoe F Morton, John Hennessy, Ray D Page, Rena M Conti,

J Oncol Pract (Journal of oncology practice)
[2014, 10(6):357-362]

Cited: 8 times

View full text PDF listing >>



The Upper Midwest Health Study: gliomas and occupational exposure to chlorinated solvents.

Avima M Ruder, James H Yiin, Martha A Waters, Tania Carreón, Misty J Hein, Mary A Butler, Geoffrey M Calvert, Karen E Davis-King, Paul A Schulte, Jack S Mandel, Roscoe F Morton, Douglas J Reding, Kenneth D Rosenman, Patricia A Stewart, ,

Occupational exposure to chlorinated aliphatic solvents has been associated with an increased cancer risk, including brain cancer. However, many of these solvents remain in active, large-volume use. We evaluated glioma risk from non-farm occupational exposure (ever/never and estimated cumulative exposure) to any of the six chlorinated solvents--carbon tetrachloride, chloroform, methylene ... Read more >>

Occup Environ Med (Occupational and environmental medicine)
[2013, 70(2):73-80]

Cited: 5 times

View full text PDF listing >>



The Upper Midwest Health Study: industry and occupation of glioma cases and controls.

Avima M Ruder, Martha A Waters, Tania Carreón, Mary A Butler, Geoffrey M Calvert, Karen E Davis-King, Kathleen M Waters, Paul A Schulte, Jack S Mandel, Roscoe F Morton, Douglas J Reding, Kenneth D Rosenman, ,

Understanding glioma etiology requires determining which environmental factors are associated with glioma. Upper Midwest Health Study case-control participant work histories collected 1995-1998 were evaluated for occupational associations with glioma. "Exposures of interest" from our study protocol comprise our a priori hypotheses.Year-long or longer jobs for 1,973 participants were assigned Standard ... Read more >>

Am. J. Ind. Med. (American journal of industrial medicine)
[2012, 55(9):747-755]

Cited: 5 times

View full text PDF listing >>



The Upper Midwest Health Study: a case-control study of pesticide applicators and risk of glioma.

James H Yiin, Avima M Ruder, Patricia A Stewart, Martha A Waters, Tania Carreón, Mary Ann Butler, Geoffrey M Calvert, Karen E Davis-King, Paul A Schulte, Jack S Mandel, Roscoe F Morton, Douglas J Reding, Kenneth D Rosenman, ,

BACKGROUND: An excess incidence of brain cancer in farmers has been noted in several studies. The National Institute for Occupational Safety and Health developed the Upper Midwest Health Study (UMHS) as a case-control study of intracranial gliomas and pesticide uses among rural residents. Previous studies of UMHS participants, using "ever-never" ... Read more >>

Environ Health (Environmental health : a global access science source)
[2012, 11:39]

Cited: 4 times

View full text PDF listing >>



A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326.

Grace K Dy, Shauna L Hillman, Kendrith M Rowland, Julian R Molina, Preston D Steen, Donald B Wender, Suresh Nair, Sumithra Mandrekar, Steven E Schild, Alex A Adjei, ,

The current study was conducted to assess the efficacy and toxicity of sorafenib as front-line therapy in patients with stage IIIB (pleural effusion) or IV nonsmall cell lung cancer (NSCLC).Patients received sorafenib 400 mg twice daily by mouth continuously, and were evaluated every 2 weeks during the first 8 weeks. ... Read more >>

Cancer (Cancer)
[2010, 116(24):5686-5693]

Cited: 26 times

View full text PDF listing >>



CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphoma.

Nadia N Laack, Brian Patrick O'Neill, Karla V Ballman, Judith Rich O'Fallon, Xiomara W Carrero, Paul J Kurtin, Bernd W Scheithauer, Paul D Brown, Thomas M Habermann, Joseph P Colgan, Mark R Gilbert, Roland B Hawkins, Roscoe F Morton, Harry E Windschitl, Tom R Fitch, Eduardo R Pajon, ,

To assess the efficacy and toxicity of chemotherapy consisting of cyclophosphamide, doxorubicin (Adriamycin), vincristine, and dexamethasone (CHOD) plus bis-chloronitrosourea (BCNU), cytosine arabinoside, and methotrexate (BVAM) followed by whole-brain irradiation (WBRT) for patients with primary central nervous system lymphoma (PCNSL).Patients 70 years old and younger with newly diagnosed, biopsy-proven PCNSL received ... Read more >>

Int. J. Radiat. Oncol. Biol. Phys. (International journal of radiation oncology, biology, physics)
[2011, 81(2):476-482]

Cited: 6 times

View full text PDF listing >>



Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741.

Howard L McLeod, Daniel J Sargent, Sharon Marsh, Erin M Green, Cristi R King, Charles S Fuchs, Ramesh K Ramanathan, Stephen K Williamson, Brian P Findlay, Stephen N Thibodeau, Axel Grothey, Roscoe F Morton, Richard M Goldberg,

With three available chemotherapy drugs for advanced colorectal cancer (CRC), response rate (RR) and survival outcomes have improved with associated morbidity, accentuating the need for tools to select optimal individualized treatment. Pharmacogenetics identifies the likelihood of adverse events or response based on variants in genes involved in drug transport, metabolism, ... Read more >>

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2010, 28(20):3227-3233]

Cited: 100 times

View full text PDF listing >>



Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM.

Kurt A Jaeckle, Karla V Ballman, Caterina Giannini, Paula J Schomberg, Matthew M Ames, Joel M Reid, Renee M McGovern, Stephanie L Safgren, Evanthia Galanis, Joon H Uhm, Paul D Brown, Julie E Hammack, Robert Arusell, Daniel A Nikcevich, Roscoe F Morton, Donald B Wender, Jan C Buckner,

Irinotecan has radiosensitizing effects and shows synergism with nitrosoureas. We performed a Phase II study of RT and irinotecan, followed by BCNU plus irinotecan in newly-diagnosed GBM. The MTD for patients receiving enzyme-inducing anticonvulsants (EIAC) was as follows: irinotecan 400 mg/m(2)/week on Days 1, 8, 22 and 29 during RT, ... Read more >>

J. Neurooncol. (Journal of neuro-oncology)
[2010, 99(1):73-80]

Cited: 3 times

View full text PDF listing >>



NCCTG Study N9741: leveraging learning from an NCI Cooperative Group phase III trial.

Richard M Goldberg, Daniel J Sargent, Roscoe F Morton, Erin Green, Hanna K Sanoff, Howard McLeod, Jan Buckner,

N9741 is a clinical trial in patients with metastatic colorectal cancer that was originally written in 1997 and completed patient accrual in 2004. One thousand seven hundred thirty-one patients were enrolled in the study. During the conduct of the trial, N9741 was repeatedly modified to adapt to toxicity findings, to ... Read more >>

Oncologist (The oncologist)
[2009, 14(10):970-978]

Cited: 8 times

View full text PDF listing >>



Exposure to farm crops, livestock, and farm tasks and risk of glioma: the Upper Midwest Health Study.

Avima M Ruder, Tania Carreón, Mary Ann Butler, Geoffrey M Calvert, Karen E Davis-King, Martha A Waters, Paul A Schulte, Jack S Mandel, Roscoe F Morton, Douglas J Reding, Kenneth D Rosenman, ,

Some studies of brain cancer have found an excess risk for farmers. The National Institute for Occupational Safety and Health previously found no increased glioma risk for ever (vs. never) being exposed to pesticides on a farm among 798 cases and 1,175 population-based controls (adult (ages 18-80 years) nonmetropolitan residents ... Read more >>

Am. J. Epidemiol. (American journal of epidemiology)
[2009, 169(12):1479-1491]

Cited: 13 times

View full text PDF listing >>



ASCO Provisional Clinical Opinion: KRAS, Cetuximab, and Panitumumab-Clinical Implications in Colorectal Cancer.

Roscoe F Morton, Elizabeth H Hammond,

ASCO's Provisional Clinical Opinion alerts oncologists to emerging information from recent clinical trials that can assist them in treatment selection. Evidence suggests that cetuximab and panitumumab are ineffective in patients with KRAS mutations at codon 12 or 13. Thus, patients with colorectal cancer with these mutations should be spared the ... Read more >>

J Oncol Pract (Journal of oncology practice)
[2009, 5(2):71-72]

Cited: 13 times

View full text PDF listing >>



Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A.

Domingo G Perez, Vera J Suman, Tom R Fitch, Thomas Amatruda, Roscoe F Morton, Shamim Z Jilani, Costas L Constantinou, James R Egner, Lisa A Kottschade, Svetomir N Markovic,

Vascular endothelial growth factor (VEGF) plays an important role in the growth and metastatic progression of melanoma. Exposure of melanoma cells to chemotherapy induces VEGF overproduction, which in turn may allow melanoma cells to evade cell death and become chemotherapy resistant. Therefore, in patients with metastatic melanoma, the combination of ... Read more >>

Cancer (Cancer)
[2009, 115(1):119-127]

Cited: 75 times

View full text PDF listing >>



American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.

Carmen J Allegra, J Milburn Jessup, Mark R Somerfield, Stanley R Hamilton, Elizabeth H Hammond, Daniel F Hayes, Pamela K McAllister, Roscoe F Morton, Richard L Schilsky,

An American Society of Clinical Oncology (ASCO) provisional clinical opinion (PCO), offers timely clinical direction to ASCO's oncologists following publication or presentation of potentially practice-changing data from major studies. This PCO addresses the utility of KRAS gene mutation testing in patients with metastatic colorectal carcinoma to predict response to anti-epidermal ... Read more >>

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2009, 27(12):2091-2096]

Cited: 625 times

View full text PDF listing >>



A dose-escalation study of aerosolized sargramostim in the treatment of metastatic melanoma: an NCCTG Study.

Svetomir N Markovic, Vera J Suman, Wendy K Nevala, Louis Geeraerts, Edward T Creagan, Lori A Erickson, Kendrith M Rowland, Roscoe F Morton, William L Horvath, Mark R Pittelkow,

Early testing of aerosolized sargramostim therapy demonstrated anecdotal clinical responses in patients with metastatic melanoma associated with emergence of systemic antitumor immunity. To improve the clinical and immunologic efficacy of therapy without compromising patient safety, we performed a further dose escalation trial in patients with metastatic melanoma.We conducted a dose-escalation ... Read more >>

Am. J. Clin. Oncol. (American journal of clinical oncology)
[2008, 31(6):573-579]

Cited: 10 times

View full text PDF listing >>



Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741.

Hanna K Sanoff, Daniel J Sargent, Megan E Campbell, Roscoe F Morton, Charles S Fuchs, Ramesh K Ramanathan, Stephen K Williamson, Brian P Findlay, Henry C Pitot, Richard M Goldberg,

In this report, we update survival (OS) and time-to-progression (TTP) data for the Intergroup trial N9741 after a median 5 years of follow-up by using risk-stratified and prognostic factor analyses to determine if treatment outcomes differ in specific patient subgroups.A total of 1,691 patients were randomly assigned to one of ... Read more >>

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2008, 26(35):5721-5727]

Cited: 139 times

View full text PDF listing >>



Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.

Paul D Brown, Sunil Krishnan, Jann N Sarkaria, Wenting Wu, Kurt A Jaeckle, Joon H Uhm, Francois J Geoffroy, Robert Arusell, Gaspar Kitange, Robert B Jenkins, John W Kugler, Roscoe F Morton, Kendrith M Rowland, Paul Mischel, William H Yong, Bernd W Scheithauer, David Schiff, Caterina Giannini, Jan C Buckner, ,

Epidermal growth factor receptor (EGFR) amplification in glioblastoma multiforme (GBM) is a common occurrence and is associated with treatment resistance. Erlotinib, a selective EGFR inhibitor, was combined with temozolomide (TMZ) and radiotherapy (RT) in a phase I/II trial.Adults not taking enzyme-inducing anticonvulsants after resection or biopsy of GBM were treated ... Read more >>

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2008, 26(34):5603-5609]

Cited: 129 times

View full text PDF listing >>



Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.

Alvaro Moreno-Aspitia, Roscoe F Morton, David W Hillman, Wilma L Lingle, Kendrith M Rowland, Martin Wiesenfeld, Patrick J Flynn, Tom R Fitch, Edith A Perez,

We conducted a cooperative group phase II study to assess antitumor activity and toxicity of sorafenib in patients with metastatic breast cancer (MBC) who had received prior treatment for their disease.Patients were eligible if they had measurable disease and had previously received an anthracycline and/or a taxane in the neoadjuvant, ... Read more >>

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2009, 27(1):11-15]

Cited: 85 times

View full text PDF listing >>



Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group.

Stephen M Ansell, David J Inwards, Kendrith M Rowland, Patrick J Flynn, Roscoe F Morton, Dennis F Moore, Scott H Kaufmann, Irene Ghobrial, Paul J Kurtin, Matthew Maurer, Christine Allmer, Thomas E Witzig,

The objective of this study was to test a low dose of (25 mg weekly) of the mammalian target of rapamycin kinase inhibitor temsirolimus for patients with relapsed mantle cell lymphoma (MCL).Patients with relapsed or refractory MCL were eligible to receive temsirolimus 25 mg intravenously every week as a single ... Read more >>

Cancer (Cancer)
[2008, 113(3):508-514]

Cited: 127 times

View full text PDF listing >>



Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group.

David J Inwards, Paul A S Fishkin, David W Hillman, David W Brown, Stephen M Ansell, Paul J Kurtin, Rafael Fonseca, Roscoe F Morton, Michael H Veeder, Thomas E Witzig,

The objective of this study was to test cladribine (2-CDA) alone and in combination with rituximab in patients with mantle cell lymphoma (MCL).Patients with MCL were treated on 2 sequential trials. In Trial 95-80-53, patients received 2-CDA as initial therapy or at relapse. In Trial N0189, patients received combination 2-CDA ... Read more >>

Cancer (Cancer)
[2008, 113(1):108-116]

Cited: 33 times

View full text PDF listing >>



A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021.

Scott H Okuno, Robert Delaune, Jeff A Sloan, Nathan R Foster, Matthew J Maurer, Marie-Christine Aubry, Kendrith M Rowland, Gamini S Soori, Daniel A Nikcevich, Carl G Kardinal, Donald W Northfelt, Alex A Adjei, ,

BACKGROUND: The North Central Cancer Treatment Group (NCCTG) conducted a phase 2 study to evaluate the antitumor activity of the combination of gemcitabine and epirubicin in patients with pleural mesothelioma who received no more than 1 prior chemotherapy regimen. METHODS: A total of 23 patients were accrued between August 2001 ... Read more >>

Cancer (Cancer)
[2008, 112(8):1772-1779]

Cited: 11 times

View full text PDF listing >>



Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741.

Grace K Dy, James E Krook, Erin M Green, Daniel J Sargent, Thierry Delaunoit, Roscoe F Morton, Charles S Fuchs, Ramesh K Ramanathan, Stephen K Williamson, Brian P Findlay, Barbara A Pockaj, Robert P Sticca, Steven R Alberts, Henry C Pitot, Richard M Goldberg, ,

To evaluate clinical characteristics and survival outcomes among patients with locally advanced or metastatic colorectal cancer who achieve a complete response (CR) to systemic treatment either alone or with multimodality approach.Data were collected retrospectively from CRC patients enrolled onto the phase III trial N9741, a National Cancer Institute-funded and Gastrointestinal ... Read more >>

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2007, 25(23):3469-3474]

Cited: 31 times

View full text PDF listing >>



Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer.

Amanda C Ashley, Daniel J Sargent, Steven R Alberts, Axel Grothey, Megan E Campbell, Roscoe F Morton, Charles S Fuchs, Ramesh K Ramanathan, Stephen K Williamson, Brian P Findlay, Henry C Pitot, Richard M Goldberg,

BACKGROUND: Efficacy and toxicity of oxaliplatin (Eloxatin; Sanofi-Aventis, Paris, France) combined with irinotecan (IROX) were examined in 383 patients enrolled on the IROX arm of Intergroup Study N9741. METHODS: This IROX regimen was oxaliplatin 85 mg/m(2) and irinotecan 200 mg/m(2) administered every 3 weeks. The relation between adverse events on ... Read more >>

Cancer (Cancer)
[2007, 110(3):670-677]

Cited: 17 times

View full text PDF listing >>



Advertisement

Disclaimer
2.2497 s